Otros idiomas Merck & Co., Inc.

Acciones

MRK

US58933Y1055

Farmacéuticos

Mercado cerrado - NYSE Otros sitios de cotización 22:03:18 11/06/2026			Después del cierre 01:55:06
120,76 ^USD	+1,40 %		121,31	+0,46 %

11/06	Los desarrolladores de fármacos contra la obesidad se posicionan ante un mercado lucrativo y una competencia creciente	RE
11/06	Merck adquiere la tecnológica avícola Targan para reforzar su división de salud animal	MT

Otros idiomas

11/06	Weight-loss drug developers line up to tap lucrative market as competition heats up
11/06	Merck Bolsters Animal-Health Unit With Deal to Buy Targan
11/06	Merck to Acquire Poultry Biodevice Firm Targan to Expand Animal Health Tech
11/06	Merck to Acquire Poultry Biodevice Firm Targan to Expand Animal Health Tech
11/06	Merck Animal Health to Acquire TARGAN
11/06	BioInvent’s TNFR2 Antibody BI-1808 Delivers Meaningful Responses and Immune Activation as Single Agent and in Combination with KEYTRUDA® (pembrolizumab) in Advanced CTCL (EHA 2026)
09/06	What Bundibugyo Ebola vaccines and treatments are under development
09/06	Weight-loss drug developers line up to tap lucrative market as competition heats up
09/06	Cancer vaccines based on mRNA advance, despite US cuts
09/06	Bourse : GSK s'offre Nuvalent pour 10,6 MdsUSD, RIP le SCAF, Orange seul maître à bord en Espagne
09/06	La tech se remet la tête à l'endroit
08/06	Gilead, Merck HIV Combination Meets Primary Endpoint in Two Phase 3 Trials
08/06	Merck, Gilead End Lung Cancer Trial, Report Positive Data From HIV Drug Trials
08/06	Merck, Gilead Discontinue Phase 3 Trial of Trodelvy, Keytruda to Treat Lung Cancer
08/06	Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
08/06	Gilead Sciences, Inc. And Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, An Oral Once-Weekly HIV Treatment
08/06	Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
08/06	Merck and Gilead Sciences, Inc. Provides Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
04/06	Merck to Pay Over $50 Million to Settle More Than 200 Gardasil Cases
04/06	Merck to Pay Over $50 Million to Settle More Than 200 Gardasil Cases, Bloomberg Reports
04/06	MÄRKTE USA/Uneinheitlich - Gewinnmitnahmen im Technologiesektor
04/06	What Bundibugyo Ebola vaccines and treatments are under development
04/06	MÄRKTE USA/Uneinheitlich - Gewinnmitnahmen im Technologiesektor
03/06	HEALTH ROUNDS-Radiation-emitting implant improves outcomes after brain cancer surgery
03/06	Avis d'analystes du jour : Richemont, ST et Publicis entourées